Advanced Biomed Finalizes Reverse Stock Split to Combat Nasdaq Delisting

summarizeSummary

Advanced Biomed Inc. has filed a definitive information statement confirming the approval of a reverse stock split, a critical measure aimed at raising its share price to maintain its Nasdaq listing following a recent delisting notice.

check_boxKey Events

• Reverse Stock Split Confirmed

  The company's majority stockholders and Board of Directors have approved a reverse stock split with a ratio ranging from 1:2 to 1:100, to be determined by the Board.

• Purpose to Maintain Nasdaq Listing

  The primary objective of the reverse stock split is to increase the per share trading price of the common stock to regain compliance with Nasdaq's minimum bid price rule and avoid delisting.

• Anticipated Effective Date

  The reverse stock split is anticipated to become effective on February 13, 2026, following the required notice period.

• Follows Delisting Notice

  This action directly follows a Nasdaq delisting notice received on January 21, 2026, due to the company's non-compliance with the minimum bid price requirement.

auto_awesomeAnalysis

This definitive information statement formalizes the previously announced reverse stock split, a critical action for Advanced Biomed Inc. given its recent Nasdaq delisting notice. The company explicitly states the reverse split's purpose is to raise its share price to regain compliance with Nasdaq's minimum bid price rule. While a reverse split can temporarily boost share price, it does not address underlying operational issues and often signals financial distress. Investors should monitor the company's ability to sustain the higher price post-split and its progress in addressing the fundamental challenges that led to the delisting threat.